Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.41 |
| ▸ | NQO2 | P16083 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734116 | 0.78 | CA2 (0.48) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL734117 | 0.78 | CA2 (0.48) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11888654 | 0.76 | AANAT (0.65) | MTNR1A | |
| SCHEMBL7827866 | 0.72 | CA2 (0.57) | CA2MTNR1AHDAC3HDAC4HDAC1 | |
| SCHEMBL4014902 | 0.71 | CA2 (0.53) | CA2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4014824 | 0.71 | CA2 (0.55) | CA2CA12CA1MAOB | |
| SCHEMBL9747807 | 0.70 | HDAC3 (0.51) | CA2MTNR1AHDAC3HDAC4HDAC1 | |
| SCHEMBL24701835 | 0.70 | MAPT (0.52) | MTNR1AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15058146 | 0.70 | MTNR1A (0.61) | MTNR1AMTNR1BNQO2MAOB | |
| SCHEMBL31369764 | 0.70 | HDAC3 (0.54) | CA2MTNR1AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-29 | — | — | US | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| US-7598269-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2009-10-06 | — | — | US | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-17 | — | — | US | disclosed |
| US-7244764-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190753-A1 | Methods and Compositions for Treating Amyloid-Related Diseases | APP, PSEN1, PSEN2 | CA2 1343/4885MTNR1A 1429/4885HDAC3 3497/4885 |
| US-20060135403-A1 | Therapeutic formulations for the treatment of beta-amyloid related diseases | APP, IAPP, BACE1 | CA2 3208/4885MTNR1A 2428/4885HDAC3 4512/4885 |
| US-20080015180-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | CA2 1343/4885MTNR1A 1429/4885HDAC3 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.